UK Authorization for Aflibercept   - Takeaways - MDSpire

UK Authorization for Aflibercept  

MHRA clears Eylea for macular edema following retinal vein occlusion

  • March 3, 2026

  • 2 min

Share

  • 1

    The UK MHRA has authorized aflibercept 8 mg for treating visual impairment due to retinal vein occlusion.

  • 2

    This approval is based on the Phase III QUASAR trial, demonstrating non-inferior visual acuity gains compared to aflibercept 2 mg.

  • 3

    Patients receiving aflibercept 8 mg required fewer injections on average than those receiving the 2 mg formulation.

  • 4

    Over 60% of patients in the 8 mg group achieved treatment intervals of four months or longer by week 64.

  • 5

    The authorization aims to reduce injection burden while maintaining visual outcomes for patients with RVO.

Original Source(s)

UK Authorization for Aflibercept  

  • March 3, 2026

Related Content

FDA Monthly Preview: Key May Decisions to Watch

Several FDA decisions across multiple specialties are expected this month.

Video: No Evidence That AREDS Vitamins Slow GA Progression

A post hoc analysis of OAKS and DERBY data failed to support the foveal protection suggested by an earlier AREDS study.

Faster, Reliable, Patient-centered: What’s Next for SPECTRALIS<sup>®</sup>

Upcoming SPECTRALIS Software Version brings new speed, workflow flexibility, and diagnostic depth to multimodal retinal imaging

  • December 9, 2025

  • 5 min